Russ Conroy

Among patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, ponatinib plus chemotherapy yielded higher rates of minimal residual disease–negative complete remission compared with imatinib.

Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

ATG-008 combined with toripalimab produced an objective response rate of 52.4% among patients with relapsed or metastatic cervical cancer in the phase 1/2 TORCH-2 study.

The VENTANA FOLR1 RxDx Assay has received approval from the FDA for identifying epithelial ovarian cancer in patients who may be eligible for treatment with mirvetuximab soravtansine-gynx.

Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.

In patients with estrogen receptor–positive recurrent endometrial cancer, letrozole and abemaciclib combination therapy produced an objective response rate of 30% and a median progression-free survival of 9.1 months.

Interim data from the phase 1/2 TACTIC-2 trial indicated that treatment with TAC01-HER2 cell therapy produced a 67% disease control rate among a cohort of patients with HER2-positive solid tumors.

Findings from a meta-analysis highlighted an association between risk of cutaneous adverse effects and use of PI3K inhibitors across different types of cancer.

Patients with unresectable stage III non-small cell lung cancer derived the most benefit from durvalumab when combined with either oleclumab or monalizumab vs durvalumab alone.

According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.

The investigational imaging agent 89ZR-DFO-girentuximab met all primary and secondary end points, exceeding pre-determined sensitivity and specificity targets in clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

Findings from a randomized phase 3 trial indicated that brentuximab vedotin plus chemotherapy yielded a higher event-free survival rate and lowered the risk of death compared with chemotherapy alone among patients with advanced-stage Hodgkin Lymphoma.

Real-world results from the retrospective SCHOLAR-2 study provided a benchmark for survival in patients with relapsed or recurrent refractory mantle cell lymphoma who received salvage therapy following failure of initial Bruton tyrosine kinase inhibitor therapy.

A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission compared with conventional care in elderly patients with relapsed or refractory acute myeloid leukemia.

Among adult patients with low- or intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions, luspatercept-aamt improved red blood cell transfusion independence with concurrent hemoglobin increase compared with epoetin alfa.

Quality of life data from the phase 3 ARASENS study highlighted how early treatment intensification with darolutamide plus standard androgen deprivation therapy and docetaxel improved patient-relevant end points compared with placebo in the management of metastatic hormone-sensitive prostate cancer.

Oral selective estrogen receptor degrader camizestrant elicited a statistically significant and clinically meaningful progression-free survival benefit compared with fulvestrant among patients with estrogen receptor–positive locally advanced or metastatic breast cancer.

Supplemental radiation doses delivered concomitantly with hypofractionated whole breast irradiation in 15 fractions demonstrated non-inferior ipsilateral breast recurrence and similar toxicity compared with sequential boosts following whole breast irradiation in high-risk early-stage breast cancer.

Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions.

Rogaratinib showed similar efficacy and manageable safety compared with chemotherapy in the management of FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma.

Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.

Based on findings from the phase 3 CABASTY trial, a fixed 16 mg/m2 dose of cabazitaxel every 2 weeks vs 25 mg/m2 every 3 weeks reduced neutropenic complications in elderly patients with mCRPC.

Quizartinib has received priority review from the FDA for the treatment of patients with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive.

According to findings from the phase 3 PACE-B trial, genitourinary and gastrointestinal toxicities were similar among patients with prostate cancer receiving conventionally fractioned or moderately hypofractionated radiotherapy and stereotactic body radiotherapy.

A trial investigating seclidemstat for Ewing and FET-rearranged sarcomas has voluntarily paused enrollment following an unexpected death.

The European Commission based its approval of axicabtagene ciloleucel as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma on the efficacy findings of the phase 3 ZUMA-7 trial.

Findings from the phase 3 KEYNOTE-048 study indicated that long-lasting improved survival benefit can be achieved with pembrolizumab plus chemotherapy compared with cetuximab and chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.

Switch treatment with palbociclib and fulvestrant from aromatase inhibitors plus palbociclib upon onset of ESR1 blood mutations and before progression yielded better progression-free survival among those with estrogen receptor–positive, HER2-negative advanced breast cancer.